Alaris cc

DMX-10001 was dissolved in 10 mM PBS, pH 7.6, and administered via a fluid-filled catheter in the inferior vena cava versus vehicle (10 mM PBS, pH 7.4) in the control animals. Twenty min before the onset of reperfusion, an initial rapid administration was started (30 min infusion, 60 mg/kg/h, Alaris CC, Cardinal Health, Role, Switzerland), followed after 10 min of reperfusion by a lower sustained dose (23.5 h infusion, 17 mg/kg/h, Myfuser, CANOX medical Device Srl, Capurso, Italy). The dosing regimen was determined by iterative computer modeling (XenoGesis Ltd, Alderley Park, UK) (Fig. 1b), based on prior dose-finding studies in pigs (data not shown).
For blinding, all solutions of DMX-10001 and vehicle were prepared and administered by someone not involved in the experimental procedures or analysis of results.

The NO-donor PDNO was prepared as has been previously reported [10 (link)] and infused using syringe pumps (Alaris CC, Cardinal Health Rulle, Switzerland). A crystalloid hydration solution infused with 1 mL kg⁻¹ h⁻¹ (Ringer-Acetate, Fresenius Kabi) served as the placebo drug.